|
|
|
|
|
Dr. ADITI NADKARNI
|
|
|
|
|
|
|
|
|
Address 1
|
:
|
|
|
Address 2
|
:
|
|
|
Title
|
:
|
Dr.
|
|
First Name
|
:
|
ADITI
|
|
Last Name
|
:
|
NADKARNI
|
|
University/Institution
|
:
|
New York University
|
|
Phone #
|
:
|
5079931320
|
|
Email ID
|
:
|
aditinfinite@gmail.com
|
|
City
|
:
|
New York
|
|
Country
|
:
|
United States
|
|
State
|
:
|
New york
|
|
Zipcode
|
:
|
10003
|
|
|
|
|
|
|
Department
|
:
|
Biology
|
|
Company Name
|
:
|
|
|
Area of Research
|
|
Cancer biology, carcinogenesis, therapeutics
|
|
Area of Expertise
|
|
cancer, DNA repair, experimental therapeutics, pharmacology
|
|
Brief Description of Research Interest :
|
|
I am a pharmacist with a doctoral degree in cancer biology and postdoctoral experience in clinical/translational research at Mayo Clinic. My doctoral research was in the area of basic cancer biology, DNA repair and my postdoctoral work was in the areas of clinical and translational brain cancer research. At Mayo Clinic, I characterized two novel pharmaceutical anticancer agents in brain cancer chemo sensitization. Here at NYU, my project evaluates cellular and genomic responses to environmental carcinogens.
In addition to research articles in peer-reviewed journals, I have experience in science journalism and my book review was published in the June21st, 2013 issue of Science magazine. I have presented my findings at both,national and international meetings, such as the American Association for Cancer Research (AACR) meeting, the Midwest DNA Repair Symposium and the NYU Abu Dhabi Systems Biology & Genomics Conference. My background in pharmaceutical sciences has provided me with a strong understanding of the scientific and pharmaceutical process.
|
|
Representative Publications :
|
1. Mignen O, Brink C, Enfissi A, Mignen O, Brink C, Enfissi A, Nadkarni A, Shuttleworth TJ, Giovannucci DR, Capiod T. Carboxyamidotriazole-induced inhibition of mitochondrial calcium import blocks capacitative calcium entry and cell proliferation in HEK-293 cells. Journal of Cell Science 2005;118(Pt 23):5615-23.
2. Nadkarni A, Furda A, Rajesh C, McInnes C, Ruch RJ, Pittman DL. Functional
characterization of the RAD51D E233G genetic variant. Pharmacogenetics and Genomics 2009;19(2):153-60. 3. Nadkarni A, Rajesh P, Ruch RJ, Pittman DL. Cisplatin resistance conferred by the RAD51D (E233G) genetic variant is dependent upon p53 status in human breast carcinoma cell lines. Molecular Carcinogenesis 2009;48(7):586-91.
4. Nadkarni A, Shrivastav M, Mladek C A, Schwingler M P, Grogan C P, Chen J, Sarkaria N J. ATM inhibitor KU-55933 increases the TMZ responsiveness of only inherently TMZ sensitive GBM cells. J Neurooncol. 2012 Dec;110(3):349-57
5. Nadkarni A, Mladek C A, Kawashima R, Mueller D, Sarkaria N J. DNA-PK inhibitor, KU-
60648 sensitizes GBM cells to radiation by increasing radiation induced DNA damage and depleting the CD133+ stem-like neurosphere population (Manuscript pending submission)
6. Nadkarni, Aditi. "Tracing a Translocation's Impact." Science 340.6139 (2013): 1407-1408.
|
|
Resume
|
:
|
Download
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|